CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.950
-0.130 (-3.19%)
At close: Dec 5, 2025, 4:00 PM EST
4.070
+0.120 (3.04%)
After-hours: Dec 5, 2025, 6:40 PM EST
CytomX Therapeutics Employees
As of December 31, 2024, CytomX Therapeutics had 121 total employees, including 119 full-time and 2 part-time employees. The number of employees decreased by 1 or -0.82% compared to the previous year.
Employees
121
Change (1Y)
-1
Growth (1Y)
-0.82%
Revenue / Employee
$939,099
Profits / Employee
$231,554
Market Cap
669.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CTMX News
- 11 days ago - CytomX Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 18 days ago - CytomX Therapeutics: Leaning Into The Hype, But What's Next? - Seeking Alpha
- 23 days ago - CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 25 days ago - Targeting Adhesion Molecules With ADC's: The Bet Of CytomX - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Top Biotech Stocks Riding The Rally - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire